Logo image of ELVN

ENLIVEN THERAPEUTICS INC (ELVN) Stock Fundamental Analysis

NASDAQ:ELVN - Nasdaq - US29337E1029 - Common Stock - Currency: USD

19.09  -1.3 (-6.38%)

Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to ELVN. ELVN was compared to 198 industry peers in the Pharmaceuticals industry. While ELVN has a great health rating, there are worries on its profitability. ELVN does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

ELVN had negative earnings in the past year.
In the past year ELVN has reported a negative cash flow from operations.
In the past 5 years ELVN reported 4 times negative net income.
ELVN had a negative operating cash flow in each of the past 5 years.
ELVN Yearly Net Income VS EBIT VS OCF VS FCFELVN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 -20M -40M -60M -80M -100M

1.2 Ratios

ELVN has a Return On Assets (-27.33%) which is in line with its industry peers.
ELVN's Return On Equity of -28.73% is fine compared to the rest of the industry. ELVN outperforms 62.12% of its industry peers.
Industry RankSector Rank
ROA -27.33%
ROE -28.73%
ROIC N/A
ROA(3y)-17.29%
ROA(5y)-32.18%
ROE(3y)-18.6%
ROE(5y)-34.76%
ROIC(3y)N/A
ROIC(5y)N/A
ELVN Yearly ROA, ROE, ROICELVN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 2024 0 -50 -100 -150

1.3 Margins

ELVN does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ELVN Yearly Profit, Operating, Gross MarginsELVN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 2024

More info and screens

8

2. Health

2.1 Basic Checks

ELVN has more shares outstanding than it did 1 year ago.
The number of shares outstanding for ELVN has been increased compared to 5 years ago.
ELVN has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
ELVN Yearly Shares OutstandingELVN Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M
ELVN Yearly Total Debt VS Total AssetsELVN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

2.2 Solvency

ELVN has an Altman-Z score of 36.73. This indicates that ELVN is financially healthy and has little risk of bankruptcy at the moment.
With an excellent Altman-Z score value of 36.73, ELVN belongs to the best of the industry, outperforming 96.46% of the companies in the same industry.
There is no outstanding debt for ELVN. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 36.73
ROIC/WACCN/A
WACCN/A
ELVN Yearly LT Debt VS Equity VS FCFELVN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 100M 200M 300M

2.3 Liquidity

A Current Ratio of 19.99 indicates that ELVN has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 19.99, ELVN belongs to the top of the industry, outperforming 92.93% of the companies in the same industry.
ELVN has a Quick Ratio of 19.99. This indicates that ELVN is financially healthy and has no problem in meeting its short term obligations.
ELVN's Quick ratio of 19.99 is amongst the best of the industry. ELVN outperforms 92.93% of its industry peers.
Industry RankSector Rank
Current Ratio 19.99
Quick Ratio 19.99
ELVN Yearly Current Assets VS Current LiabilitesELVN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

More info and screens

1

3. Growth

3.1 Past

The Earnings Per Share has grown by an nice 13.70% over the past year.
EPS 1Y (TTM)13.7%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%2.13%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, ELVN will show a quite strong growth in Earnings Per Share. The EPS will grow by 12.34% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-19.72%
EPS Next 2Y-18.72%
EPS Next 3Y-18.78%
EPS Next 5Y12.34%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
ELVN Yearly Revenue VS EstimatesELVN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2025 2026 2027 2028 2029 2030 2031 2032 200M 400M 600M
ELVN Yearly EPS VS EstimatesELVN Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 5 -5 -10 -15

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

ELVN reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ELVN. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ELVN Price Earnings VS Forward Price EarningsELVN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 -10 20

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ELVN Per share dataELVN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 6

4.3 Compensation for Growth

ELVN's earnings are expected to decrease with -18.78% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-18.72%
EPS Next 3Y-18.78%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for ELVN!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ENLIVEN THERAPEUTICS INC

NASDAQ:ELVN (5/6/2025, 12:51:09 PM)

19.09

-1.3 (-6.38%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)03-13 2025-03-13/amc
Earnings (Next)05-08 2025-05-08
Inst Owners85.96%
Inst Owner Change0%
Ins Owners5.62%
Ins Owner Change3.69%
Market Cap936.75M
Analysts85.71
Price Target38.91 (103.82%)
Short Float %19.75%
Short Ratio27
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)9.4%
Min EPS beat(2)5.29%
Max EPS beat(2)13.51%
EPS beat(4)4
Avg EPS beat(4)13.14%
Min EPS beat(4)5.29%
Max EPS beat(4)27.01%
EPS beat(8)5
Avg EPS beat(8)3.2%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0.75%
PT rev (3m)0.75%
EPS NQ rev (1m)0%
EPS NQ rev (3m)11.83%
EPS NY rev (1m)0.44%
EPS NY rev (3m)5.61%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 3.02
P/tB 3.02
EV/EBITDA N/A
EPS(TTM)-1.89
EYN/A
EPS(NY)-2.26
Fwd EYN/A
FCF(TTM)-1.49
FCFYN/A
OCF(TTM)-1.49
OCFYN/A
SpS0
BVpS6.31
TBVpS6.31
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -27.33%
ROE -28.73%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-17.29%
ROA(5y)-32.18%
ROE(3y)-18.6%
ROE(5y)-34.76%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 13.88%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 19.99
Quick Ratio 19.99
Altman-Z 36.73
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)41.02%
Cap/Depr(5y)30.61%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)13.7%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%2.13%
EPS Next Y-19.72%
EPS Next 2Y-18.72%
EPS Next 3Y-18.78%
EPS Next 5Y12.34%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-25.17%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-26.94%
EBIT Next 3Y-34.52%
EBIT Next 5YN/A
FCF growth 1Y-19.24%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-19.46%
OCF growth 3YN/A
OCF growth 5YN/A